BioMérieux
Experimental treatment arm(BioMérieux)은 HER2 표적 ADC로, Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) 영역에서 개발·상용화 중입니다. 작용기전: targeted therapies such as antisense oligonucleotides (ASO) or small interfering RNA (siRNA) can rapidly reduce hepatitis B surface antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 61건의 관련 임상이 등록되어 있습니다. 차별점: novel regimens for the treatment of pulmonary tuberculosis.
HER2
Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Recruiting
bispecific antibody dual-targeting TSLP and IL-13, for the suppression
deruxtecan plus fluoropyrimidine versus standard c
novel regimens for the treatment of pulmonary tuberculosis
targeted therapies such as antisense oligonucleotides (ASO) or small interfering RNA (siRNA) can rapidly reduce hepatitis B surface antigen
apoptosis in the target cell
HER2-positive
Resistance to androgen receptor pathway inhibitors (ARPIs) such as darolutamide signals impending metastatic progression of prostate
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
BioMérieux
Experimental treatment arm(BioMérieux)은 HER2 표적 ADC로, Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) 영역에서 개발·상용화 중입니다. 작용기전: targeted therapies such as antisense oligonucleotides (ASO) or small interfering RNA (siRNA) can rapidly reduce hepatitis B surface antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 61건의 관련 임상이 등록되어 있습니다. 차별점: novel regimens for the treatment of pulmonary tuberculosis.
HER2
Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Recruiting
bispecific antibody dual-targeting TSLP and IL-13, for the suppression
deruxtecan plus fluoropyrimidine versus standard c
novel regimens for the treatment of pulmonary tuberculosis
targeted therapies such as antisense oligonucleotides (ASO) or small interfering RNA (siRNA) can rapidly reduce hepatitis B surface antigen
apoptosis in the target cell
HER2-positive
Resistance to androgen receptor pathway inhibitors (ARPIs) such as darolutamide signals impending metastatic progression of prostate
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.